SPYD vs XBI
SPDR Portfolio S&P 500 High Dividend ETF vs SPDR S&P Biotech ETF
- • SPYD has the lower expense ratio at 0.07% vs 0.35% for XBI.
- • SPYD pays a higher dividend yield (4.20%).
Side-by-side metrics
| Metric | SPYD | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.07% | 0.35% |
Dividend yield Trailing 12-month yield. | 4.20% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $7.64B | $10.92B |
YTD return | 19.42% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.55 | 1.01 |
P/E ratio | 15.99 | — |
Last price | $49.87 | $156.41 |
Inception | — | — |
Issuer | State Street | State Street |
SPYD top holdings
| ACN | Accenture PLC Class A | 2.35% |
| HAS | Hasbro Inc | 1.71% |
| PFE | Pfizer Inc | 1.57% |
| CVX | Chevron Corp | 1.56% |
| MDT | Medtronic PLC | 1.51% |
| SWK | Stanley Black & Decker Inc | 1.48% |
| EOG | EOG Resources Inc | 1.47% |
| HPQ | HP Inc | 1.46% |
| CCI | Crown Castle Inc | 1.46% |
| AMT | American Tower Corp | 1.44% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About SPYD
SPYD (SPDR Portfolio S&P 500 High Dividend ETF) is Top 80 highest-yielding S&P 500 stocks. Managed by State Street, the fund carries $7.6B in assets under management, an expense ratio of 0.07%, a dividend yield of 4.20%. Its largest holding is Accenture PLC Class A (ACN), which represents 2.4% of the portfolio. Real Estate is the fund's largest sector exposure at 24.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.